VIVOS THERAPEUTICS INC
VVOSNASDAQ🏆 #3721 by market capUS Equity
$0.30▼ $0.02 (−7.40%)
Live1h—
24h▼ 7.4%
7d▼ 34.9%
14d▼ 28.9%
30d▼ 31.1%
1y▼ 93.4%
🏦Market Cap
$4M
Small Cap
📈Revenue Growth (YoY)
+33.8%
High Growth
📊Gross Margin
61.8%
High
💵FCF Margin
—
⚖️P/S Ratio
0.2x
Cheap
Otter Score
46
Weak
Trading Snapshot
- Day Range
- $0.30 – $0.30
- 52-Week Range
- $0.30 – $5.12
- Volume
- $5.25B
- Avg Volume
- $3.61B
- Shares Outstanding
- 13.9M
- Next Earnings
- Sep 2, 2026
Fundamentals Snapshot
- Annual Revenue
- $25M
- Last Q Revenue
- $6M
- P/E Ratio
- —
- P/S Ratio
- 0.2x
- EPS (TTM)
- $-2.12
- Dividend Yield
- —
Why Investors Own VVOS
- ✓High-growth profile — revenue up +47.4% YoY with expanding US Equity exposure.
- ✓Healthy economics — 78% gross margin and 22% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$25M▲ +43.9% YoY
Gross Margin (TTM)
77.9%▲ +0.8% YoY
Operating Income (TTM)
$5M▲ +43.9% YoY
Free Cash Flow (TTM)
$5M▲ +43.9% YoY
About VIVOS THERAPEUTICS INC
A company profile for VIVOS THERAPEUTICS INC isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Weak
46/100
Analyst Price Target
ⓘAverage Target
$0.31
▲ +2.4% Upside
High Target$0.37
Low Target$0.26
Based on 20 analysts
Latest News & Updates
🚀
MarketWatch·2h ago
VIVOS THERAPEUTICS INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
Bloomberg·5h ago
Analysts lift VVOS price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
MarketWatch·1d ago
VIVOS THERAPEUTICS INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.